|
125 Companies |
|
183 Products |
|
183 Products |
|
133 Mechanisms of Action |
|
1 Trial |
|
2306 News |
|
| «12...2930313233343536373839...4041» |
- New P1 trial: Exercise in Severely Disabled Patients With MS (clinicaltrials.gov) - Dec 17, 2012
P1, N=12, Completed, Sponsor: University of Aarhus
- Campath (alemtuzumab) / Sanofi
Trial termination: Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Systemic Sclerosis (clinicaltrials.gov) - Dec 13, 2012
P1, N=8, Terminated, Sponsor: Richard Burt, MD
Recruiting --> Terminated; No subject enrolled since 2009
- Campath (alemtuzumab) / Sanofi
Enrollment change: Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Systemic Sclerosis (clinicaltrials.gov) - Dec 13, 2012
P1, N=8, Terminated, Sponsor: Richard Burt, MD
Recruiting --> Terminated; No subject enrolled since 2009 N=10 --> 8
- Enrollment change, Combination therapy: SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov) - Dec 10, 2012
P2, N=141, Completed, Sponsor: National Cancer Institute (NCI)
N=10 --> 8 N=33 --> 141
- || Rituxan (rituximab) / Roche
New P2/3 trial: Rituximab in Systemic Sclerosis (clinicaltrials.gov) - Dec 10, 2012
P2/3, N=90, Recruiting, Sponsor: Assistance Publique - H
- ||||| mecobalamin (E0302) / Eisai
Enrollment closed: A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Dec 5, 2012
P2/3, N=300, Active, not recruiting, Sponsor: Eisai Co., Ltd.
N=33 --> 141 Recruiting --> Active, not recruiting
- Trial initiation date: ALSCELL: Creation of a Bank of Fibroblast From Patients With Amyotrophic Lateral Sclerosis: Pilot Study (clinicaltrials.gov) - Dec 4, 2012
P=N/A, N=30, Recruiting, Sponsor: Institut Pasteur
Recruiting --> Active, not recruiting Initiation date: Aug 2012 --> Nov 2012
- New P2 trial: Treatment of Pendular Nystagmus With Gabapentin and Memantine in Patients With Multiple Sclerosis (clinicaltrials.gov) - Dec 4, 2012
P2, N=10, Completed, Sponsor: Hospices Civils de Lyon
- Enrollment open: ALSCELL: Creation of a Bank of Fibroblast From Patients With Amyotrophic Lateral Sclerosis: Pilot Study (clinicaltrials.gov) - Dec 4, 2012
P=N/A, N=30, Recruiting, Sponsor: Institut Pasteur
Initiation date: Aug 2012 --> Nov 2012 Not yet recruiting --> Recruiting
- | MIS416 / Amplia Therap
Enrollment change, Immunomodulating: Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis (clinicaltrials.gov) - Dec 4, 2012
P1/2, N=34, Completed, Sponsor: Innate Therapeutics Limited
Not yet recruiting --> Recruiting N=24 --> 34
- | MIS416 / Amplia Therap
Trial completion, Immunomodulating: Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis (clinicaltrials.gov) - Dec 4, 2012
P1/2, N=34, Completed, Sponsor: Innate Therapeutics Limited
N=24 --> 34 Active, not recruiting --> Completed
- ||||| amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
New P2 trial: Dose-finding Study of MT-1303 (clinicaltrials.gov) - Dec 3, 2012
P2, N=400, Recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
- | Enrollment change: Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients (clinicaltrials.gov) - Dec 2, 2012
P2, N=38, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed N=324 --> 38
- | Trial completion: Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients (clinicaltrials.gov) - Dec 2, 2012
P2, N=38, Completed, Sponsor: GlaxoSmithKline
N=324 --> 38 Active, not recruiting --> Completed
- ||||||| dalfampridine / Generic mfg.
Trial completion: Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis (clinicaltrials.gov) - Nov 29, 2012
P3, N=430, Completed, Sponsor: Acorda Therapeutics
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment change: Randomized, Controlled Trial to Test the Efficacy of Interferon Beta in the Treatment of Intermediate Uveitis (clinicaltrials.gov) - Nov 29, 2012
P3, N=19, Completed, Sponsor: University of Heidelberg
Active, not recruiting --> Completed N=34 --> 19
- Trial completion: Randomized, Controlled Trial to Test the Efficacy of Interferon Beta in the Treatment of Intermediate Uveitis (clinicaltrials.gov) - Nov 29, 2012
P3, N=19, Completed, Sponsor: University of Heidelberg
N=34 --> 19 Recruiting --> Completed
- | New P1 trial: Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS). (clinicaltrials.gov) - Nov 28, 2012
P1, N=30, Recruiting, Sponsor: GE Healthcare
- Biomarker: A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis (clinicaltrials.gov) - Nov 27, 2012
P=N/A, N=45, Recruiting, Sponsor: John F. Foley, MD
- Enrollment open: Vestibular Rehabilitation for Persons With Multiple Sclerosis: Who Benefits the Most? (MSVR3trial) (clinicaltrials.gov) - Nov 27, 2012
P=N/A, N=88, Recruiting, Sponsor: University of Colorado, Denver
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||| sodium chlorite (NP001) / Neuvivo
Enrollment change: A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Nov 19, 2012
P2, N=136, Completed, Sponsor: Neuraltus Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting N=105 --> 136
- Enrollment change: Lido Workset Study (clinicaltrials.gov) - Nov 19, 2012
P=N/A, N=31, Completed, Sponsor: Mark Agius, MD
N=105 --> 136 N=75 --> 31
- |||| sodium chlorite (NP001) / Neuvivo
Trial completion: A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Nov 19, 2012
P2, N=136, Completed, Sponsor: Neuraltus Pharmaceuticals, Inc.
N=75 --> 31 Active, not recruiting --> Completed
- Trial completion: Lido Workset Study (clinicaltrials.gov) - Nov 19, 2012
P=N/A, N=31, Completed, Sponsor: Mark Agius, MD
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | New P2 trial: CISAVID: Dose-related Effects of Vitamin D3 on Immune Responses in Patients With Clinically Isolated Syndrome (clinicaltrials.gov) - Nov 18, 2012
P2, N=84, Recruiting, Sponsor: University College Dublin
- Enrollment change: NETALS: Neuromuscular Transmission in Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Nov 15, 2012
P=N/A, N=14, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Active, not recruiting --> Completed N=30 --> 14
- Trial completion: NETALS: Neuromuscular Transmission in Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Nov 15, 2012
P=N/A, N=14, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
N=30 --> 14 Recruiting --> Completed
- Rebif (human IFN-?-1a) / EMD Serono
Trial completion, Combination therapy: Combination Therapy Using Cellcept and Rebif in RRMS (clinicaltrials.gov) - Nov 13, 2012
P0, N=31, Completed, Sponsor: Aaron Boster
Recruiting --> Completed Active, not recruiting --> Completed
- | ceftriaxone / Generic mfg.
Trial completion: Clinical Trial Ceftriaxone in Subjects With ALS (clinicaltrials.gov) - Nov 12, 2012
P3, N=513, Completed, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Tysabri (natalizumab) / Biogen, Royalty
Trial termination, MRI: Magnetic Resonance Imaging (MRI) Follow-up of Macrophagic Infiltration in MS Patients Treated With Tysabri (clinicaltrials.gov) - Nov 8, 2012
P4, N=8, Terminated, Sponsor: University Hospital, Strasbourg, France
Active, not recruiting --> Completed Completed --> Terminated
- Enrollment open: Oral Testosterone for Fatigue in Male Multiple Sclerosis Patients (clinicaltrials.gov) - Nov 8, 2012
P2, N=50, Recruiting, Sponsor: Health Sciences Centre, Winnipeg, Manitoba
Completed --> Terminated Not yet recruiting --> Recruiting
- Enrollment closed: inMotion: Motivational Interviewing to Increase Physical Activity to Treat Depression in People Aging With MS or SCI (clinicaltrials.gov) - Nov 7, 2012
P=N/A, N=108, Active, not recruiting, Sponsor: University of Washington
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Enrollment closed: TakeCharge: Telephone Delivered Self-management Intervention for People With Multiple Sclerosis (MS) (clinicaltrials.gov) - Nov 7, 2012
P=N/A, N=120, Active, not recruiting, Sponsor: University of Washington
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Clinical: TRAP-Myéline: Analyze the Myelin-TRAP as Diagnostic Tool in Multiple Sclerosis (clinicaltrials.gov) - Nov 6, 2012
P=N/A, N=100, Recruiting, Sponsor: Nantes University Hospital
- ||||| teriflunomide / Generic mfg.
Enrollment change: TOPIC: Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis (clinicaltrials.gov) - Nov 4, 2012
P3, N=618, Active, not recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting N=780 --> 618
- ||||| teriflunomide / Generic mfg.
Enrollment closed: TOPIC: Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis (clinicaltrials.gov) - Nov 4, 2012
P3, N=618, Active, not recruiting, Sponsor: Sanofi
N=780 --> 618 Recruiting --> Active, not recruiting
- dalfampridine / Generic mfg.
Enrollment closed: FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra (clinicaltrials.gov) - Nov 1, 2012
P4, N=125, Active, not recruiting, Sponsor: University of Southern Denmark
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Trial completion: A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis (clinicaltrials.gov) - Nov 1, 2012
P1, N=40, Completed, Sponsor: Oregon Health and Science University
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Plegridy (PEG-interferon ?-1a) / Biogen
Trial completion: Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy Volunteers (clinicaltrials.gov) - Oct 31, 2012
P1, N=30, Completed, Sponsor: Biogen Idec
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
New P2 trial: Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis (clinicaltrials.gov) - Oct 30, 2012
P2, N=30, Recruiting, Sponsor: Anders Svenningsson
- | Trial initiation date: DOSERAL: Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls (clinicaltrials.gov) - Oct 29, 2012
P3, N=80, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Active, not recruiting --> Completed Initiation date: Oct 2010 --> Oct 2012
- lithium carbonate ER / Generic mfg.
Enrollment change: LISLA: Effect of Lithium Carbonate in Patients With Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Oct 29, 2012
P2, N=23, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Initiation date: Oct 2010 --> Oct 2012 N=200 --> 23
- New P2 trial: Effect of Melatonin on Multiple Sclerosis Related Fatigue (clinicaltrials.gov) - Oct 29, 2012
P2, N=44, Completed, Sponsor: Isfahan University of Medical Sciences
- lithium carbonate ER / Generic mfg.
Trial completion: LISLA: Effect of Lithium Carbonate in Patients With Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Oct 29, 2012
P2, N=23, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
N=200 --> 23 Not yet recruiting --> Completed
- | Orenitram (treprostinil diethanolamine oral) / United Therapeutics Corp
Trial termination: DISTOL-EXT: Open-Label Study of Oral Treprostinil in Digital Ulcers (clinicaltrials.gov) - Oct 29, 2012
P2, N=115, Terminated, Sponsor: United Therapeutics
Not yet recruiting --> Completed Active, not recruiting --> Terminated; The TDE-DU-202 extension study was discontinued after the randomized, placebo-controlled TDE-DU-201 study did not meet its primary efficacy objective.
- Orenitram (treprostinil diethanolamine oral) / United Therapeutics Corp
Enrollment change: DISTOL-EXT: Open-Label Study of Oral Treprostinil in Digital Ulcers (clinicaltrials.gov) - Oct 29, 2012
P2, N=115, Terminated, Sponsor: United Therapeutics
Active, not recruiting --> Terminated; The TDE-DU-202 extension study was discontinued after the randomized, placebo-controlled TDE-DU-201 study did not meet its primary efficacy objective. N=150 --> 115
- | Myoconda (clarithromycin/clofazimine/rifabutin) / RedHill
New P2a trial: CEASE-MS: Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Oct 28, 2012
P2a, N=16, Recruiting, Sponsor: RedHill Biopharma Limited
- Enrollment open: Brain Functional Connectivity Changes Following Cognitive Rehabilitation in Multiple Sclerosis: an fMRI Study (clinicaltrials.gov) - Oct 28, 2012
P=N/A, N=30, Recruiting, Sponsor: Sina Hospital, Iran
N=150 --> 115 Not yet recruiting --> Recruiting
- Trial withdrawal: Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis (clinicaltrials.gov) - Oct 28, 2012
P2, N=0, Withdrawn, Sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Not yet recruiting --> Recruiting Not yet recruiting --> Withdrawn
- Enrollment change: Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis (clinicaltrials.gov) - Oct 28, 2012
P2, N=0, Withdrawn, Sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Not yet recruiting --> Withdrawn N=40 --> 0